Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MK 8776

Drug Profile

MK 8776

Alternative Names: MK-8776; SCH 900776

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co
  • Class Antineoplastics; Pyrazoles; Pyrimidines
  • Mechanism of Action Cell cycle inhibitors; Checkpoint kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Cancer; Lymphoma; Solid tumours

Most Recent Events

  • 01 May 2013 Phase-II clinical trials in Acute myeloid leukaemia (combination therapy) in USA (IV)
  • 21 Feb 2012 Schering-Plough terminates a phase I trial in Leukaemia (combination therapy) in USA (NCT00907517)
  • 22 Jun 2011 Schering-Plough completes a phase I trial in Solid tumours and Lymphomas (combination therapy) in US (NCT00779584)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top